PL366119A1 - Treatment of anxiety disorders - Google Patents

Treatment of anxiety disorders

Info

Publication number: PL366119A1
Authority: PL; Poland
Prior art keywords: treatment; anxiety disorders; anxiety; disorders
Prior art date: 2000-11-15

Application number

PL01366119A

Other languages

Polish (pl)

Inventor

Holly Read Thomasson

David Michelson

Original Assignee

Eli Lilly And Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-15

Filing date

2001-11-06

Publication date

2005-01-24

2001-11-06 Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company

2005-01-24 Publication of PL366119A1 publication Critical patent/PL366119A1/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Investigating Or Analysing Biological Materials (AREA)

PL01366119A 2000-11-15 2001-11-06 Treatment of anxiety disorders PL366119A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US24901000P	2000-11-15	2000-11-15
US26536201P	2001-01-31	2001-01-31

Publications (1)

Publication Number	Publication Date
PL366119A1 true PL366119A1 (en)	2005-01-24

Family

ID=26939750

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL01366119A PL366119A1 (en)	2000-11-15	2001-11-06	Treatment of anxiety disorders

Country Status (16)

Country	Link
EP (1)	EP1395253A2 (en)
JP (1)	JP2004529073A (en)
KR (1)	KR20030051812A (en)
CN (1)	CN1822825A (en)
AU (1)	AU2002217757A1 (en)
BR (1)	BR0115301A (en)
CA (1)	CA2426069A1 (en)
CZ (1)	CZ20031339A3 (en)
EA (1)	EA200300567A1 (en)
HR (1)	HRP20030384A2 (en)
IL (1)	IL155874A0 (en)
MX (1)	MXPA03004190A (en)
NO (1)	NO20032156L (en)
PL (1)	PL366119A1 (en)
SK (1)	SK5422003A3 (en)
WO (1)	WO2002040006A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH695982A5 (en) *	2001-03-06	2006-11-15	Lilly Co Eli	Inhibitor of Monaminaufnahme.
CN1674907A (en) *	2002-08-14	2005-09-28	法玛西亚普强责任有限公司	Use of reboxetine for the treatment of hot flashes
GB0309440D0 (en) *	2003-04-25	2003-06-04	Lilly Co Eli	Quinolone derivatives
WO2004103356A2 (en) *	2003-05-15	2004-12-02	Eli Lilly And Company	Treatment of emotional dysregulation
EP1729754B1 (en) *	2003-12-12	2008-07-02	Eli Lilly And Company	Selective norepinephrine reuptake inhibitors for the treatment of hot flashes
EP2234960A2 (en)	2008-01-09	2010-10-06	Mayo Foundation for Medical Education and Research	Inhibiting neurotransmitter reuptake
WO2011056788A2 (en) *	2009-11-03	2011-05-12	Mayo Foundation For Medical Education And Research	Inhibiting neurotransmitter reuptake
US20120220665A1 (en) *	2009-11-03	2012-08-30	Mayo Foundation For Medical Education And Research	Inhibiting Neurotransmitter Reuptake
US9944618B2 (en)	2013-03-14	2018-04-17	Mayo Foundation For Medical Education And Research	Inhibiting neurotransmitter reuptake
CN113710319B (en) *	2019-02-01	2024-10-11	霍夫曼技术有限责任公司	Compositions and methods for treating anxiety-related disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997041878A1 (en) *	1996-05-07	1997-11-13	Merck & Co., Inc.	Treatment of mood disorders with a growth hormone secretagogue
IT1305322B1 (en) *	1998-04-23	2001-05-04	Pharmacia & Upjohn Spa	Use of reboxetine for treating obsessive compulsive disorder and panic disorder
KR100717660B1 (en) *	1999-07-01	2007-05-15	파마시아 앤드 업존 캄파니 엘엘씨	Highly Selective Norepinephrine Reuptake Inhibitors and Methods of Using the Same

2001
- 2001-11-06 PL PL01366119A patent/PL366119A1/en not_active Application Discontinuation
- 2001-11-06 JP JP2002542380A patent/JP2004529073A/en active Pending
- 2001-11-06 CA CA002426069A patent/CA2426069A1/en not_active Abandoned
- 2001-11-06 EA EA200300567A patent/EA200300567A1/en unknown
- 2001-11-06 SK SK542-2003A patent/SK5422003A3/en not_active Application Discontinuation
- 2001-11-06 WO PCT/US2001/027801 patent/WO2002040006A2/en not_active Application Discontinuation
- 2001-11-06 AU AU2002217757A patent/AU2002217757A1/en not_active Abandoned
- 2001-11-06 CN CNA01818927XA patent/CN1822825A/en active Pending
- 2001-11-06 EP EP01996376A patent/EP1395253A2/en not_active Withdrawn
- 2001-11-06 KR KR10-2003-7006523A patent/KR20030051812A/en not_active Application Discontinuation
- 2001-11-06 IL IL15587401A patent/IL155874A0/en unknown
- 2001-11-06 BR BR0115301-3A patent/BR0115301A/en not_active IP Right Cessation
- 2001-11-06 MX MXPA03004190A patent/MXPA03004190A/en unknown
- 2001-11-06 CZ CZ20031339A patent/CZ20031339A3/en unknown
2003
- 2003-05-13 NO NO20032156A patent/NO20032156L/en not_active Application Discontinuation
- 2003-05-14 HR HR20030384A patent/HRP20030384A2/en not_active Application Discontinuation

Also Published As

Publication number	Publication date
HRP20030384A2 (en)	2003-08-31
IL155874A0 (en)	2003-12-23
NO20032156D0 (en)	2003-05-13
WO2002040006A3 (en)	2003-12-24
JP2004529073A (en)	2004-09-24
EA200300567A1 (en)	2004-10-28
CA2426069A1 (en)	2002-05-23
MXPA03004190A (en)	2003-09-22
AU2002217757A1 (en)	2002-05-27
CZ20031339A3 (en)	2003-10-15
BR0115301A (en)	2004-12-14
NO20032156L (en)	2003-05-13
EP1395253A2 (en)	2004-03-10
CN1822825A (en)	2006-08-23
SK5422003A3 (en)	2003-12-02
KR20030051812A (en)	2003-06-25
WO2002040006A2 (en)	2002-05-23

Publication	Publication Date	Title
GB0007193D0 (en)	2000-05-17	Treatment of movrmrnt disorders
AU8187701A (en)	2002-01-14	Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders
IL155589A0 (en)	2003-11-23	Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
AU9527001A (en)	2002-04-22	Treatment of T cell disorders
AU2002360555A8 (en)	2003-06-23	Treatment of genitourinary tract disorders
HRP20030384A2 (en)	2003-08-31	Treatment of anxiety disorders
IL150479A0 (en)	2002-12-01	Treatment of psoriasis
IL150290A0 (en)	2002-12-01	The use of mirtazapine for the treatment of sleep disorders
IL140540A0 (en)	2002-02-10	Treatment of anxiety disorders
SI1468686T1 (en)	2007-04-30	S-methyl-dihydro-ziprasidone for treatment of psychiatric disorders
IL151493A0 (en)	2003-04-10	Use of dermaciclane for the treatment of anxiety and depression
EP1303281A4 (en)	2006-02-15	Methods of treatment
GB0017951D0 (en)	2000-09-13	Treatment of movement disorders
GB0010496D0 (en)	2000-06-14	Treatment of conditions of the central nervous system
HUP0301798A3 (en)	2004-03-01	Treatment of eating disorders using carboxyalkylethers
GB0003228D0 (en)	2000-04-05	Treatment of GI disorders
GB0029955D0 (en)	2001-01-24	Treatment of neuropsychiatric disorders
GB0125371D0 (en)	2001-12-12	Treatment of movement disorders
GB0021060D0 (en)	2000-10-11	Treatment of functional gastrointestinal disorders
GB9924942D0 (en)	1999-12-22	Treatment of movement disorders
GB0013928D0 (en)	2000-08-02	Methods of treatment
GB0014904D0 (en)	2000-08-09	Methods of treatment
GB0004998D0 (en)	2000-04-19	The treatment of functional gastrointestinal disorders
GB0024704D0 (en)	2000-11-22	Treatment of hyperproliferative skin disorders
GB0219811D0 (en)	2002-10-02	Treatment of excreta

Legal Events

Date	Code	Title	Description
2009-07-31	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)